Science & Technology

This article outlines current U.S. government processes to bolster biosecurity and biosafety measures and summarizes five key findings from biosecurity experts.

In recent years, there has been an increased focus on finding treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, as the prevalence of these diseases continues to rise globally. This blog aims to provide an overview of the sources and trends of funding for neurodegenerative disease research, with a particular focus on comparing funding for these diseases with that of other classes of diseases. By examining historical funding trends and the current sources of funding, we seek to shed light on the current state of the funding ecosystem for neurodegenerative disease research. We will also explore how funding is allocated across different types of neurodegenerative diseases and discuss potential bottlenecks in the funding process that may be hindering progress in the development of therapies.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

Neurodegenerative diseases (NDDs) are a class of disorders that cause the progressive loss of structure or function of neurons, leading to declines in cognitive and physical abilities. Drug discovery and development for these diseases is a complex, multi-stakeholder process involving a variety of entities across the United States, including government agencies, businesses, research institutions, academic institutions, and non-profit organizations. These stakeholders interact with each other at various stages of the non-linear cycle of drug development, which typically involves a range of activities including pre-clinical research, clinical trials, regulatory approval, and commercialization.

Given the complexity of this process and the challenges involved in developing effective treatments for NDDs, it is important to better understand the role of different stakeholders and the potential barriers they face. This blog aims to provide a deeper examination of the various stakeholders involved in NDD drug discovery and development, and to offer an initial hypothesis on key challenges that may be contributing to the lack of disease-altering therapies for these conditions.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

Neurodegenerative diseases (NDD) such as Alzheimer’s, Parkinson’s, and ALS represent a global health crisis affecting more than nine million people in the United States alone. NDDs are caused by progressive loss of central nervous system neurons - currently, there is no cure to reverse this loss. The only approved therapies are palliative or mildly reduce some symptoms. In this blog, the author introduces ways technology and public policy can improve the drug discover process to "cure the uncureable" - setting the stage for his larger research project this academic year.

Ivan Arreguin-Toft analyzes the West's information technology asymmetry of capability, which has given way to asymmetry of vulnerability. While democracies worldwide remain threatened, they also contain the means to restore themselves.

Hostile foreign states are using weaponized information to attack the United States. Russia and China are disseminating disinformation about domestic U.S. race relations and COVID-19 to undermine and discredit the U.S. government. These information warfare attacks, which threaten U.S. national security, may seem new, but they are not. Using an applied history methodology and a wealth of previously classified archival records, this article uses two case studies to reveal how and why a hostile foreign state, the Soviet Union, targeted America with similar disinformation in the past

Ivan Arreguin-Toft argues that non-material considerations like cyber power matter just as much as material ones in debates about U.S. retrenchment from the Middle East.

Paul Joskow, the Elizabeth and James Killian Professor of Economics emeritus at MIT and former President and CEO of the Alfred P. Sloan Foundation in New York City, shared his thoughts on U.S. regulatory economics and climate change policy in the latest episode of “Environmental Insights: Discussions on Policy and Practice from the Harvard Environmental Economics Program.”

.

Even if formal cybersecurity treaties are unworkable, it may still be possible to set limits on certain types of civilian targets, and to negotiate rough rules of the road. Whether U.S. President Joe Biden succeeded in launching such a process at his meeting last month with Russian President Vladimir Putin may become clear soon.

Henry Farrell and Bruce Schneier argue that organizations that deliberately fabricate citizen voices shouldn't just be subject to civil fines, but to criminal penalties. Businesses that hire these organizations should be held liable for failures of oversight as well.